Company intelligence / Profile preview

Optina Diagnostics

Montreal, Quebec, Canadafacebook.com ↗

Ownership: Private
Development stage: Commercial

Overview

Optina Diagnostics has developed the Retinal Deep Phenotyping™ digital biomarker platform using a proprietary hyperspectral retinal camera and AI-driven analytics. Their lead product, the awAIr™–CAS test, non-invasively detects cerebral amyloid status—a key Alzheimer’s disease marker—using retinal imaging. The device received FDA Breakthrough Device Designation and its pivotal validation study (“REPHRASE”) is ongoing. The company also targets age-related macular degeneration with its technology. No therapeutics are in development; focus remains on diagnostics.

Therapeutic areas: CardiovascularOphthalmologyNeurology
Modalities: Device (hyperspectral retinal camera)Artificial intelligence (AI-driven image analysis)Digital biomarker platform
Industry: Medical Imaging

Beyond the preview

Go deeper on Optina Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optina Diagnostics.

Explore the full profile